Insmed Incorporated (NASDAQ:INSM) Holdings Lifted by Handelsbanken Fonder AB

Handelsbanken Fonder AB boosted its position in Insmed Incorporated (NASDAQ:INSM - Free Report) by 8.6% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 49,181 shares of the biopharmaceutical company's stock after purchasing an additional 3,900 shares during the quarter. Handelsbanken Fonder AB's holdings in Insmed were worth $3,752,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in the company. Darwin Global Management Ltd. increased its stake in shares of Insmed by 23.5% during the 4th quarter. Darwin Global Management Ltd. now owns 12,960,538 shares of the biopharmaceutical company's stock valued at $894,796,000 after acquiring an additional 2,463,261 shares during the last quarter. Norges Bank acquired a new position in shares of Insmed during the 4th quarter valued at about $126,606,000. Vanguard Group Inc. increased its stake in shares of Insmed by 6.3% during the 4th quarter. Vanguard Group Inc. now owns 18,218,973 shares of the biopharmaceutical company's stock valued at $1,257,838,000 after acquiring an additional 1,075,796 shares during the last quarter. Brown Advisory Inc. acquired a new position in shares of Insmed during the 4th quarter valued at about $45,773,000. Finally, Adage Capital Partners GP L.L.C. increased its stake in shares of Insmed by 59.6% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 1,647,562 shares of the biopharmaceutical company's stock valued at $113,748,000 after acquiring an additional 615,000 shares during the last quarter.

Insider Activity

In other news, CEO William Lewis sold 18,750 shares of the firm's stock in a transaction on Monday, March 17th. The stock was sold at an average price of $77.03, for a total transaction of $1,444,312.50. Following the transaction, the chief executive officer now directly owns 334,186 shares of the company's stock, valued at approximately $25,742,347.58. This trade represents a 5.31% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Sara Bonstein sold 57,766 shares of the firm's stock in a transaction on Tuesday, June 10th. The shares were sold at an average price of $89.12, for a total value of $5,148,105.92. Following the transaction, the chief financial officer now directly owns 103,412 shares in the company, valued at $9,216,077.44. This trade represents a 35.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 319,932 shares of company stock valued at $25,733,693. Company insiders own 3.00% of the company's stock.

Analysts Set New Price Targets

INSM has been the subject of a number of research reports. Leerink Partners boosted their target price on Insmed from $100.00 to $115.00 and gave the stock an "outperform" rating in a report on Tuesday, June 10th. Morgan Stanley boosted their target price on Insmed from $90.00 to $102.00 and gave the stock an "overweight" rating in a report on Wednesday. Royal Bank of Canada upped their price target on Insmed from $99.00 to $106.00 and gave the stock an "outperform" rating in a report on Wednesday. Stifel Nicolaus decreased their price target on Insmed from $97.00 to $96.00 and set a "buy" rating for the company in a report on Friday, February 21st. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of Insmed in a report on Wednesday, February 19th. One research analyst has rated the stock with a sell rating and eighteen have given a buy rating to the company. Based on data from MarketBeat.com, Insmed presently has a consensus rating of "Moderate Buy" and a consensus price target of $104.81.

Insmed Stock Performance

NASDAQ INSM traded up $1.85 during trading hours on Friday, hitting $98.73. The company had a trading volume of 5,318,455 shares, compared to its average volume of 2,164,284. Insmed Incorporated has a fifty-two week low of $60.40 and a fifty-two week high of $100.00. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03. The business has a fifty day simple moving average of $71.41 and a 200-day simple moving average of $73.59. The firm has a market cap of $17.98 billion, a P/E ratio of -17.66 and a beta of 0.80.

Insmed (NASDAQ:INSM - Get Free Report) last issued its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share for the quarter, missing the consensus estimate of ($1.36) by ($0.06). The company had revenue of $92.82 million during the quarter, compared to analyst estimates of $91.63 million. Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. Insmed's quarterly revenue was up 22.9% on a year-over-year basis. During the same period in the prior year, the business earned ($1.06) earnings per share. Equities analysts predict that Insmed Incorporated will post -4.56 EPS for the current year.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.